Back to Search
Start Over
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- Source :
- Clinical Pharmacokinetics
- Publication Year :
- 2021
-
Abstract
- Background Vericiguat, a stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for worsening chronic heart failure in adults with left ventricular ejection fraction < 45%. Objective The objective of this article was to characterize the pharmacokinetics and pharmacokinetic variability of vericiguat combined with guideline-directed medical therapy (standard of care), and identify exposure–response relationships for safety (hemodynamics) and pharmacodynamic markers of efficacy (N-terminal pro-B-type natriuretic peptide concentration [NT-proBNP]) in patients with heart failure and left ventricular ejection fraction < 45% in the SOCRATES-REDUCED study (NCT01951625). Methods Vericiguat and NT-proBNP plasma concentrations in 454 and 432 patients in SOCRATES-REDUCED, respectively, were analyzed using nonlinear mixed-effects modeling. Results Vericiguat pharmacokinetics were well described by a one-compartment model with apparent clearance, apparent volume of distribution, and absorption rate constant. Age, bodyweight, plasma bilirubin, and creatinine clearance were identified as significant covariates on apparent clearance; sex and bodyweight on apparent volume of distribution; and bodyweight and plasma albumin level on absorption rate constant. Pharmacokinetic/pharmacodynamic analysis showed initial minor and transient effects of vericiguat on blood pressure with low clinical impact. There were no changes in heart rate following initial or repeated vericiguat administration. An exposure-dependent and time-dependent turnover pharmacokinetic/pharmacodynamic model for NT-proBNP described production and elimination rates and an demonstrated exposure-dependent reduction in [NT-proBNP] by vericiguat plus standard of care compared with placebo plus standard of care. This effect was dependent on baseline [NT-proBNP]. Conclusions Vericiguat has predictable pharmacokinetics, with no long-term effects on blood pressure in patients with heart failure and left ventricular ejection fraction < 45%. A pharmacokinetic/pharmacodynamic model described a vericiguat exposure-dependent reduction of NT-proBNP. Clinical Trial Identifier NCT01951625. Supplementary Information The online version contains supplementary material available at 10.1007/s40262-021-01024-y.
- Subjects :
- medicine.medical_specialty
Renal function
Hemodynamics
030204 cardiovascular system & hematology
Heterocyclic Compounds, 2-Ring
Ventricular Function, Left
03 medical and health sciences
0302 clinical medicine
Pharmacokinetics
Internal medicine
Natriuretic Peptide, Brain
Medicine
Humans
Pharmacology (medical)
030212 general & internal medicine
Original Research Article
Pharmacology
Volume of distribution
Heart Failure
Ejection fraction
business.industry
Stroke Volume
medicine.disease
Peptide Fragments
Blood pressure
Pyrimidines
Pharmacodynamics
Heart failure
Cardiology
business
Biomarkers
Subjects
Details
- ISSN :
- 11791926
- Volume :
- 60
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Clinical pharmacokinetics
- Accession number :
- edsair.doi.dedup.....060b376d3024cbe1cbc5c71300a70b49